Tissue Regenix Group PLC Long term distribution agreement with Arthrex, Inc (7649G)
06 March 2018 - 6:01PM
UK Regulatory
TIDMTRX
RNS Number : 7649G
Tissue Regenix Group PLC
06 March 2018
Tissue Regenix Group plc
CellRight Technologies signs multi-year distribution agreement
with Arthrex, Inc.
Leeds, 06 March 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company
today announces subsidiary CellRight Technologies ("CellRight") has
signed a long-term, multi-year distribution agreement with Arthrex,
Inc., a premier innovator of orthopaedic surgical solutions.
CellRight, which produces industry leading verified
osteobiologics for use in orthopaedic, spine and foot and ankle
procedures, enhances the healing opportunities of defects caused by
trauma and disease.
The multi-year commitment will give surgeons access to verified
osteobiologics and advanced surgical instrumentation and techniques
to help influence better patient outcomes.
"This long-term distribution agreement will allow physicans and
patients better access to CellRight's innovative orthobiologics
through the Arthrex network," said Jesus Hernandez, CEO for
CellRight Technologies. "Our shared vision of offering surgeons
total solutions which can positively impact patient outcomes
solidifies the decision of both companies to work together."
Steve Couldwell, CEO Tissue Regenix Group plc commented: "This
is a flagship distribution agreement for CellRight and the wider
Tissue Regenix Group. It highlights the value of strategic
partnerships with prestigious companies in this space. We look
forward to working with Arthrex to bring the CellRight product
portfolio to an extended network of healthcare professionals."
CellRight Technologies and TRX Orthopedics, will be exhibiting
at the American Academy of Orthopaedic Surgeons in New Orleans,
March 7-10 and can be found at booth #5413.
For more Information:
Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Head of Communications 430 3073
/ 07920272
441
---------------------------------------- ------------
Jefferies International Ltd Tel: 020
Simon Hardy / Christopher Binks 7029 8000
---------------------------------------- ------------
FTI Consulting Tel: 0203
Brett Pollard / Mo Noonan/ Rob Winder 727 1000
======================================== ============
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
rebranded TRX BioSurgery in February 2018. January 2016 saw the
establishment of joint venture GBM-V, a multi- tissue bank based in
Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTJAMBTMBBMTFP
(END) Dow Jones Newswires
March 06, 2018 02:01 ET (07:01 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024